Novo Nordisk Total Liabilities 2012-2026 | NVO

Novo Nordisk total liabilities for the quarter ending March 31, 2026 were $55.774B, a 12.74% increase year-over-year.

  • Novo Nordisk total liabilities for 2025 were $52.817B, a 13.01% increase from 2024.
  • Novo Nordisk total liabilities for 2024 were $46.735B, a 54.8% increase from 2023.
  • Novo Nordisk total liabilities for 2023 were $30.191B, a 35.14% increase from 2022.

Novo Nordisk Total Liabilities 2012-2026 | NVO

  • Novo Nordisk total liabilities for 2025 were $52.817B, a 13.01% increase from 2024.
  • Novo Nordisk total liabilities for 2024 were $46.735B, a 54.8% increase from 2023.
  • Novo Nordisk total liabilities for 2023 were $30.191B, a 35.14% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B